We are inviting you to take part in a clinical study for adults with IgA Nephropathy (IgAN). Participants do not have to pay for the study drugs, study-specific visits, or tests and procedures that are a part of the study. In addition, you may be reimbursed for your travel. No health insurance is required to participate.
What happens if I sign up?
We will match you to a study center in your area that needs volunteers with IgA Nephropathy (IgAN) or notify you when one becomes available. The study team will then contact you and you may have the opportunity to participate if qualified.
If you think you might like to participate in the ARTEMIS-IGAN Clinical Study or would like more information, please enter your information below so we can see if you may qualify and can contact you about the study. Keep in mind that participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.
Worldwide, Immunoglobulin A Nephropathy (IgAN) is the most common disease that effects the kidneys. IgAN is an immune-mediated disease that results in inflammation and injury to the kidneys.
For many people, symptoms of Immunoglobulin A Nephropathy (IgAN) don’t show up until the disease has progressed and can sometimes not appear for years. Many experience:
There is no cure for Immunoglobulin A Nephropathy (IgAN), however some individuals are able to manage their condition with medication from their doctor.
The purpose of the IgAN Studies is to test the safety and describe the effect of an investigational medicine, in people with IgA Nephropathy.
A clinical trial, also referred to as a research study, is a scientific study that evaluates the safety and efficacy of an investigational medication. A research study may show that the investigational medication is better than, as good as, or worse than the standard treatment or inactive placebo. Qualified doctors, nurses and other medical professionals will conduct the study.
It is only through the completion of research studies that investigational medication can be evaluated, and if proven safe and effective, approved for general use by appropriate regulatory or health authorities, such as the U.S. Food and Drug Administration (FDA). Prescription medications in use today were first proven safe and effective in research studies.
When you sign up for a research study, your personal information is protected as required by law. The research team stores personal and private information with codes (instead of names or other identifying information), in order to not identify the participant or volunteer. The informed consent form that will be provided to you by the research team will have more information about privacy protection.
Participants who are eligible and take part in the study may receive compensation for time and travel. Please discuss this with the research site staff when they contact you.
This study will use a new investigational medication in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damages the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess fluid and waste (and other toxins) from your blood stream.
The purpose of this study is to test the safety and describe the effect of an investigational medicine, in people with IgA Nephropathy.